Asia Leaders
Noubar Afeyan Oversaw Moderna’s $2.2 Billion Cost Reset. The Cash Runway Is the Board’s Next Test
Noubar Afeyan’s most consequential job in 2026 is chairing Moderna through a costly transition. The board has backed deep savings and a tighter pipeline; its next obligation is to show that lower spending can produce durable medicines before cash declines too far.
